- Details
- In this conversation, Fred Saad discusses the PEACE-3 trial results. The study compares enzalutamide plus radium-223 versus enzalutamide alone in metastatic castration-resistant prostate cancer patients with bone metastases. Dr. Saad discusses the trial's design, highlighting significant improvements in radiographic progression-free survival and overall survival with the combination therapy. They...
|
- Details
- Rashid Sayyid and Zach Klaassen review the 2024 NCCN prostate cancer guideline updates focusing on treatment-related bone loss in patients on androgen deprivation therapy (ADT). They emphasize the importance of addressing bone health due to increased fracture risk associated with ADT. The speakers outline a comprehensive approach to bone health management, including risk assessment using the FRAX...
|
- Details
- Alicia Morgans interviews Alan Bryce about his session on radiopharmaceutical therapies for mCRPC with bone metastases, focusing on the decision-making between radium-223 and lutetium-177. Dr. Bryce explains the session aimed at practical clinical decision-making, emphasizing the underlying science of radiopharmaceuticals, including the distinctions between alpha and beta emitters and their target...
|
- Details
- Neal Shores joins Alicia Morgans in conversation to discuss the RALU study. RALU is a retrospective analysis that sought to evaluate the safety and clinical outcomes of sequential radium-223/177Lu-PSMA therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). The study found that patients tolerated Lutetium-177 well, and PSA and alkaline phosphatase declines were observed....
|
- Details
- Kambiz Rahbar joins Alicia Morgans to discuss a post hoc analysis of the RALU study, which looks at the time interval between radium and lutetium-PSMA treatment and its effect on the safety and effectiveness of lutetium treatment in patients with metastatic castration-resistant prostate cancer. This analysis aimed to assess the safety and survival outcomes with lutetium when treatment began within...
|
- Details
- In this conversation, Alicia Morgans and Oliver Sartor discuss the safety and efficacy data from the RALU study where patients with metastatic castration-resistant prostate cancer received lutetium-177-prostate-specific membrane antigen (PSMA) with prior radium-223 treatment. The RAdium LUtetium (RALU) study evaluated the feasibility of sequential alpha and beta emitter use in patients with bone-p...
|
- Details
- In this conversation, Alicia Morgans, Phillip Koo, and Neal Shore evaluate a patient case of a 63-year-old man who was diagnosed with de novo metastatic prostate cancer in January 2020. He was initially treated for metastatic hormone-sensitive prostate cancer with enzalutamide plus ADT. He presents again now with progression of bone-only metastatic disease. Drs Shore, Koo, and Morgans talk through...
|
- Details
- Urologist Neal Shore joins Alicia Morgans in a conversation on the multidisciplinary approach and successful incorporation of radium-223 dichloride (radium-223) into the treatment algorithm for men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases. Drs. Shore and Morgans talk through the challenges care teams face when planning the administration of radiu...
|
- Details
- In this discussion, Nicholas James and Alicia Morgans discuss the relationship between alkaline phosphatase decline and overall survival in men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases treated with radium-223 (Ra-223) in the global real-world REASSURE study. REASSURE is evaluating the long-term safety of Radium 223 in routine clinical practice in...
|
- Details
- In this UroToday Journal Club Chris Wallis and Zach Klaassen highlight a Journal of Nuclear Medicine publication entitled Safety and Survival Outcomes of Lutetium-177-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with prior Radium-223 treatment: The RALU Study . The RAdium LUtetium (RALU) study evaluated the feasibility of sequential al...
|
